| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Karl Eugen Ruckhäberle | Q100415175 |
| Karin Milde-Langosch | Q38297224 | ||
| Thomas Karn | Q40714980 | ||
| P2093 | author name string | Tanja Fehm | |
| Volkmar Müller | |||
| Sven Becker | |||
| Achim Rody | |||
| Giampaolo Bianchini | |||
| Nicole Sänger | |||
| Uwe Holtrich | |||
| Erich Franz Solomayer | |||
| Tomas Heinrich | |||
| P2860 | cites work | Progestin effects on cell proliferation pathways in the postmenopausal mammary gland | Q21092903 |
| Bioconductor: open software development for computational biology and bioinformatics | Q21194861 | ||
| Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer | Q24605866 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development | Q28142247 | ||
| Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials | Q28275006 | ||
| RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis | Q28294501 | ||
| affy--analysis of Affymetrix GeneChip data at the probe level | Q29547353 | ||
| Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer | Q29615523 | ||
| The causes and consequences of genetic heterogeneity in cancer evolution | Q29615848 | ||
| Tackling the widespread and critical impact of batch effects in high-throughput data | Q30004214 | ||
| Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis | Q44486779 | ||
| Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases | Q45814967 | ||
| Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma | Q46448642 | ||
| Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial | Q46786144 | ||
| A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer | Q46799300 | ||
| Progesterone/RANKL is a major regulatory axis in the human breast. | Q51042996 | ||
| Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. | Q54535173 | ||
| Reporting recommendations for tumor marker prognostic studies | Q81236405 | ||
| The humoral immune system has a key prognostic impact in node-negative breast cancer | Q81561686 | ||
| Cancer. Heterogeneity and tumor history | Q83937521 | ||
| Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer | Q33448620 | ||
| The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data | Q33498527 | ||
| Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer | Q33584322 | ||
| Comparison of scores for bimodality of gene expression distributions and genome-wide evaluation of the prognostic relevance of high-scoring genes. | Q33586734 | ||
| A comparison of methods for data-driven cancer outlier discovery, and an application scheme to semisupervised predictive biomarker discovery | Q33902424 | ||
| An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival | Q33939753 | ||
| RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data | Q33966102 | ||
| Sequence analysis of mutations and translocations across breast cancer subtypes | Q34032470 | ||
| Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures | Q34119025 | ||
| Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients | Q34141028 | ||
| Use of archived specimens in evaluation of prognostic and predictive biomarkers | Q35007222 | ||
| Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials | Q35186747 | ||
| Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling | Q35194008 | ||
| A clinically relevant gene signature in triple negative and basal-like breast cancer | Q35683578 | ||
| Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients | Q35749359 | ||
| Lung metastasis genes couple breast tumor size and metastatic spread. | Q35800363 | ||
| Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer | Q36494250 | ||
| Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting | Q36709828 | ||
| Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. | Q36902695 | ||
| Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. | Q37155629 | ||
| Osteoimmunology: crosstalk between the immune and bone systems | Q37544448 | ||
| RANKL inhibition: a promising novel strategy for breast cancer treatment. | Q37865171 | ||
| Gene expression profiling in breast cancer: classification, prognostication, and prediction | Q37958156 | ||
| Effects of bone-targeted agents on cancer progression and mortality. | Q38023206 | ||
| Progesterone signalling in breast cancer: a neglected hormone coming into the limelight | Q38109029 | ||
| RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis | Q39365550 | ||
| Bimodal gene expression and biomarker discovery | Q39479059 | ||
| Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation | Q42491260 | ||
| Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes | Q42517986 | ||
| Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study | Q42829926 | ||
| The effect of a single dose of osteoprotegerin in postmenopausal women | Q43520860 | ||
| A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | Q44291815 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 1196-1207 | |
| P577 | publication date | 2014-04-15 | |
| P1433 | published in | Molecular Oncology | Q2190736 |
| P1476 | title | OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer | |
| P478 | volume | 8 |
| Q41135883 | Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer. |
| Q30240711 | Deciphering the divergent roles of progestogens in breast cancer |
| Q38699879 | Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy |
| Q90781774 | Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer |
| Q47250561 | Key Factors in Breast Cancer Dissemination and Establishment at the Bone: Past, Present and Future Perspectives. |
| Q36252676 | Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers |
| Q36273402 | Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort |
| Q28081803 | Osteoprotegerin in breast cancer: beyond bone remodeling |
| Q92134531 | Osteoprotegerin: Relationship to Breast Cancer Risk and Prognosis |
| Q36750660 | RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs |
| Q57801311 | Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort |
| Q36356112 | The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis. |
| Q40714796 | The prognostic impact of age in different molecular subtypes of breast cancer |
Search more.